Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma

NCT07324707 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Bronchial Asthma

Interventions

DRUG: PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days
DRUG: Fluticasone Propionate Inhaled Aerosol 200 μg per day for 28 days

Sponsor

Anhui Palo Alto Pharmaceuticals, Inc.